Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients
Status:
Not yet recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1 dose-escalation study of BAT6026, an OX40
monoclonal antibody, combined with the anti-PD-1 IgG4 monoclonal antibody BAT1308 in subjects
with advanced solid tumours. After a screening period of up to 28 days, qualified subjects
will be enrolled to receive their assigned dose regimen until disease progression or
intolerable toxicity, withdrawal of consent, per Investigator decision, or end of study,
whichever occurs first. The maximum treatment duration is 1 year. Subjects who remain on
treatment in the absence of disease progression for more than 1 year may continue to receive
study drug for the next cycle at the maximum of 2 years.